Background: Cemiplimab, an anti–PD-1 monoclonal antibody, is the standard of care for advanced cutaneous squamous cell carcinoma (cSCC) not amenable to curative surgery or radiotherapy. However, more than half of patients do not respond, and no reliable clinical or histopathological predictors of response have been established. Objective: To compare the clinical and histopathological features of patients who responded to cemiplimab with those who did not, and to identify predictors of response. Methods: This prospective observational study enrolled patients with advanced cSCC referred to the Institutional Tumor Board for Skin Cancer of Fondazione Policlinico Universitario Campus Bio-Medico (Rome, Italy). They were treated with cemiplimab 350 mg intravenously every 3 weeks between November 2022 and December 2025. Patient-related variables (age, sex, ECOG performance status, comorbidities, statin use), tumor-related variables (primary site, differentiation grade, thickness, perineural invasion, AJCC 8th edition stage) and prior treatments were recorded. The primary endpoint was objective response rate (ORR), assessed by RECIST v1.1 and/or WHO criteria. Responders and non-responders were compared using the χ², Fisher’s exact and Mann-Whitney U tests, followed by univariable and multivariable logistic regression. Results: Thirty-five patients were included. Median age was 81 years (IQR 71.5–87), 74.3% were male and 34.3% had an ECOG performance status ≥2. The primary tumor was in the head and neck in 71.4% of patients, and 57.1% had stage IV disease. Complete and partial responses were observed in 7 (20.0%) and 8 (22.9%) patients, respectively, for an ORR of 42.9%. Treatment-related adverse events occurred in 25.7% of patients. All were grade 1–2, and no patient discontinued treatment because of toxicity. Response rates were 81.8% in G3 tumors, compared with 14.3% in G1 and 21.4% in G2 tumors (p = 0.003). G3 tumors had higher odds of response than G1–G2 tumors at univariable analysis (OR 4.37, 95% CI 1.71–11.2; p = 0.002). This association remained significant after adjustment for primary tumor site (OR 4.04, 95% CI 1.54–10.6; p = 0.005). Head and neck location and statin use were not independent predictors. Age, performance status, comorbidities, perineural invasion, stage, nodal involvement and prior treatments were not associated with response. Conclusions: In this real-world cohort of elderly and frail patients, cemiplimab showed clinically meaningful activity and a favorable safety profile. Poor tumor differentiation was the only independent predictor of response and may identify a more immunogenic subgroup of advanced cSCC. These findings need validation in larger multicenter cohorts.
Analysis of clinical and histopathological features in patients affected by advanced cutaneous squamous cell carcinoma: a prospective study to investigate possible correlations with response to cemiplimab
Morelli Coppola, Marco
2026
Abstract
Background: Cemiplimab, an anti–PD-1 monoclonal antibody, is the standard of care for advanced cutaneous squamous cell carcinoma (cSCC) not amenable to curative surgery or radiotherapy. However, more than half of patients do not respond, and no reliable clinical or histopathological predictors of response have been established. Objective: To compare the clinical and histopathological features of patients who responded to cemiplimab with those who did not, and to identify predictors of response. Methods: This prospective observational study enrolled patients with advanced cSCC referred to the Institutional Tumor Board for Skin Cancer of Fondazione Policlinico Universitario Campus Bio-Medico (Rome, Italy). They were treated with cemiplimab 350 mg intravenously every 3 weeks between November 2022 and December 2025. Patient-related variables (age, sex, ECOG performance status, comorbidities, statin use), tumor-related variables (primary site, differentiation grade, thickness, perineural invasion, AJCC 8th edition stage) and prior treatments were recorded. The primary endpoint was objective response rate (ORR), assessed by RECIST v1.1 and/or WHO criteria. Responders and non-responders were compared using the χ², Fisher’s exact and Mann-Whitney U tests, followed by univariable and multivariable logistic regression. Results: Thirty-five patients were included. Median age was 81 years (IQR 71.5–87), 74.3% were male and 34.3% had an ECOG performance status ≥2. The primary tumor was in the head and neck in 71.4% of patients, and 57.1% had stage IV disease. Complete and partial responses were observed in 7 (20.0%) and 8 (22.9%) patients, respectively, for an ORR of 42.9%. Treatment-related adverse events occurred in 25.7% of patients. All were grade 1–2, and no patient discontinued treatment because of toxicity. Response rates were 81.8% in G3 tumors, compared with 14.3% in G1 and 21.4% in G2 tumors (p = 0.003). G3 tumors had higher odds of response than G1–G2 tumors at univariable analysis (OR 4.37, 95% CI 1.71–11.2; p = 0.002). This association remained significant after adjustment for primary tumor site (OR 4.04, 95% CI 1.54–10.6; p = 0.005). Head and neck location and statin use were not independent predictors. Age, performance status, comorbidities, perineural invasion, stage, nodal involvement and prior treatments were not associated with response. Conclusions: In this real-world cohort of elderly and frail patients, cemiplimab showed clinically meaningful activity and a favorable safety profile. Poor tumor differentiation was the only independent predictor of response and may identify a more immunogenic subgroup of advanced cSCC. These findings need validation in larger multicenter cohorts.| File | Dimensione | Formato | |
|---|---|---|---|
|
PhD_Morelli Coppola_Marco.pdf
accesso aperto
Licenza:
Creative Commons
Dimensione
607.04 kB
Formato
Adobe PDF
|
607.04 kB | Adobe PDF | Visualizza/Apri |
I documenti in UNITESI sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/20.500.14242/385809
URN:NBN:IT:UNICAMPUS-385809